Competition drives down sales of J&J’s Olysio
The company said growth in its immunology portfolio offset declining Olysio sales.
Biosimilars
Five things for pharma marketers to know: Wednesday, April 6, 2016
Pfizer and Allergan call off merger; the FDA approves second biosimilar; NEJM comes under fire
Five things for pharma marketers to know: Wednesday, March 30, 2016
There are 23 biosimilars ready to file with the FDA; an FDA committee votes in favor of Parkinson’s disease drug; Bloomberg funds new immunotherapy center
Five things for pharma marketers to know: Friday, February 12, 2016
Aegerion slashes workforce; GSK president says downward pressure on drug prices is here to stay; Novartis acquires European rights to Remicade biosimilar
With support of FDA committee, Remicade biosimilar edges closer to market
The FDA is set to announce its decision on the drug in April.
Five things for pharma marketers to know: Wednesday, February 10, 2016
SEC is investigating Salix Pharmaceuticals; FDA adcomm recommends approval of Remicade biosimilar; Medicare considers payment changes
Five things for pharma marketers to know: Tuesday, February 9, 2016
The FDA to review biosimilar Remicade; lawmaker looks at panelists’ ties to painkiller manufacturers; Novartis signs risk-sharing contracts for Entresto
Five things for pharma marketers to know: Friday, February 5, 2016
Johnson & Johnson collaborates with biotech on diabetes stem-cell treatment; the FDA warms up to Remicade biosimilar; Woodcock warns about biosimilar backlog
Five things for pharma marketers to know: Thursday, December 17, 2015
The FDA approves Lilly’s Lantus follow-on biologic; AstraZeneca buys majority stake in Acerta Pharma; Shkreli arrested on securities fraud charges
Five things for pharma marketers to know: Wednesday, November 18, 2015
Califf defends his past; Drug spending to increase by 4%-7% per year through 2020; Samsung Bioepis’s Enbrel biosimilar faces decision-date Friday
